Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk: The First Fruits Of Labor
12:27am, Friday, 15'th May 2026
Novo Nordisk has had a stellar past month at the stock markets with a 25% rise after it touched multi-year lows earlier this year. Fuelling the rise are oral Ozempic and Wegovy pill launches, alongsi
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
11:20am, Thursday, 14'th May 2026
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
Is Novo Nordisk's Rebound for Real--or Just a Head Fake?
01:15pm, Wednesday, 13'th May 2026
Novo Nordisk recently posted strong quarterly results. Newer launches are boosting sales.
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
12:52pm, Wednesday, 13'th May 2026
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.
Novo Nordisk A/S Q1 Earnings Call Highlights
05:07am, Wednesday, 13'th May 2026
Novo Nordisk A/S NYSE: NVO said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipelin
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
02:00am, Wednesday, 13'th May 2026
Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end
Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction
01:22pm, Tuesday, 12'th May 2026
Novo Nordisk A/S (NYSE:NVO) presented new sub-analyses from its STEP UP clinical trial at the European Congress on Obesity, highlighting that a higher dose of Wegovy helped people with obesity achieve
GLP-1 Wars: Winners & Losers
12:56pm, Tuesday, 12'th May 2026
With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.
Why Hims & Hers Health Stock Just Crashed
11:32am, Tuesday, 12'th May 2026
Hims and Hers is unshaken by its earnings miss, with management promising even faster sales growth this year.
The $59B Quiet Shift Reshaping How Patients Access Care
11:00am, Tuesday, 12'th May 2026
The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
10:49am, Tuesday, 12'th May 2026
Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated perso
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
10:01am, Tuesday, 12'th May 2026
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Healthy Returns: Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weight
10:00am, Tuesday, 12'th May 2026
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.
Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10 (41.4%) achieving 25% or more weight loss1. Substantial weight loss was consistent across all
Novo Nordisk Says Higher-Dose Wegovy Shot Helps Some Patients Lose 28% of Their Weight
02:48am, Tuesday, 12'th May 2026
The company said the majority of the weight loss—around 84%—came from losing body fat while preserving muscle function and improving muscle health.
